AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?

Mercy Guech-Ongey¹, Edgar P. Simard¹, William F. Anderson², Eric A. Engels¹, Kishor Bhatia¹, Susan S. Devesa², and Sam M. Mbulaiteye¹

1. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

2. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

Correspondence:

Mercy Guech-Ongey, Ph.D.
Infections and Immunoepidemiology Branch
Division of Cancer Epidemiology and Genetics
National Cancer Institute, NIH, DHHS
6120 Executive Blvd, Executive Plaza South, Rm. 7078
Rockville, MD 20852
E-mail: guechome@mail.nih.gov
Tel: (301) 594-7097
Fax: (301) 402-0817

Running title: Age and CD4 patterns in AIDS-related Burkitt lymphoma
Abstract

Trimodal or bimodal age-specific incidence rates for Burkitt lymphoma (BL) were observed in the U.S. general population, but the role of immunosuppression could not be excluded. Incidence rates, rate ratios (IRR), and 95% confidence intervals (95% CI) for BL and other non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisson regression models using data from the U.S. HIV/AIDS Cancer Match study (1980-2005). BL incidence was 22 cases per 100,000 person-years and 586 for non-BL NHL. Adjusted BL incidence rate ratio among males was 1.6 times that among females and among non-Hispanic Blacks 0.4 times that among non-Hispanic Whites, but it was unrelated to HIV-transmission category. Non-BL NHL incidence increased from childhood to adulthood; in contrast, two age-specific incidence peaks during the pediatric and adult/geriatric years were observed for BL. Non-BL NHL incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was lowest among people with ≤50 CD4 lymphocytes/µL versus those with ≥250 CD4 lymphocytes/µL (IRR 0.3 (95% CI =0.2-0.6)). The bimodal peaks for BL, in contrast to non-BL NHL, suggest effects of non-cumulative risk factors at different ages. Under-ascertainment or biological reasons may account for BL deficit at low CD4 lymphocyte counts.

Keywords: non-Hodgkin lymphoma, epidemiology, bimodal cancer, multistage cancer, HIV/AIDS, Burkitt lymphoma
Background

Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) with three clinical variants: endemic (eBL), sporadic (sBL), and acquired immunodeficiency-associated BL (aBL) 1. These clinical variants, which are defined, in part, by where they occur geographically, are histologically indistinguishable 1 and their etiology is incompletely understood 2. Endemic BL occurs in children mostly as extranodal jaw or orbital masses in equatorial Africa and Papua New Guinea 3. Sporadic BL occurs anywhere in the world at any age mostly with abdominal or nodal involvement 4-5. Immunodeficiency-associated BL is diagnosed in people with human immunodeficiency virus (HIV) 1, among whom it is often the first indication of AIDS onset at least in the West. Risk for both eBL and sBL appears to be highest at age 5-9 years and sBL rates are also elevated at the oldest ages 4,6. Because BL is a rapidly growing tumor, doubling its cell mass about every 1-2 days 7, the interval from trigger to diagnosis may be relatively short, so study of age-specific risk may provide etiologic information.

In an assessment of age-specific risk for BL in the United States, using data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program (1973 – 2005) 8, we observed three incidence peaks near ages 10, 40, and 70 years among males and two peaks near ages 10 and 70 years among females for both Whites and Blacks. However, the role of AIDS-related immunosuppression could not be excluded 9-10 because we were not able to separately analyze AIDS and non-AIDS BL. To address this limitation, we investigated age-specific BL incidence among persons with AIDS (PWA) in the
U.S. Because age is a surrogate for cumulative exposure to deleterious infections a linear increase in risk for BL with age in PWA would suggest cumulative impact of deleterious infections given immunosuppression, whereas a non-linear risk increase would suggest that age may be a surrogate for differences in the etiology or biology of BL diagnosed at different ages that occur independent of immunosuppression.

Methods

Data were obtained from the National Cancer Institute's U.S. population-based HIV/AIDS Cancer Match (HACM) study. The study links registry records of a cohort of persons with HIV/AIDS in 15 U.S. state and metropolitan areas to their corresponding cancer registry record to ascertain cancer outcomes, based on a probabilistic matching algorithm. Analysis was performed using de-identified data for 1980-2005. Institutional review boards at all participating sites gave ethical approval to conduct the study.

The primary outcome was BL morphology code 9687, based on the International Classification of Diseases for Oncology (ICD-O-3), third edition, obtained from the cancer registry. Data for other NHLs (all other NHL morphology codes excluding BL) were obtained for comparative analyses. Person-years were calculated from the date of AIDS diagnosis to the earliest of date of death, 60 months from AIDS-diagnosis, or end of cancer registry coverage. Because ascertainment of mortality of the AIDS cohort may be incomplete, we truncated follow-up at 60, which includes the period when we
expected ascertainment of mortality to be most complete, to minimize overestimating person-years of follow-up. The date of AIDS diagnosis was set to the date of BL diagnosis when the date of BL diagnosis given by the cancer registry preceded the date of AIDS diagnosis given by the AIDS registry because BL is an AIDS-defining condition. Cases diagnosed during 0 to 3 months from AIDS diagnosis were categorized as prevalent; cases diagnosed from 4 to 60 months after AIDS diagnosis were considered incident. Prevalent cases were excluded from analyses because they may be biased by characteristics related to diagnosis of AIDS and/or survival up to AIDS. Incident cases were used in analyses because they are less biased and they allow inferences about the temporal relationship between risk factors associated with disease to be made.

Mean age for prevalent versus incident BL and for prevalent versus incident other NHLs were compared using the Student’s t-test. Crude and adjusted incidence rates, rate ratios (IRR), and 95% confidence intervals (95% CI) were calculated using Poisson methods by patient characteristics: sex, race/ethnicity (non-Hispanic White, non-Hispanic Black and Hispanic), HIV transmission risk categories (men who had sex with men [MSM], intravenous drug users [IDU], heterosexual, and other), CD4 lymphocyte count categories at AIDS-diagnosis (<50, 50-149, 150-249, ≥250 cells/µL), age at AIDS diagnosis (0-19, 20-31, 32-39, 40-51, 52-59, ≥60 years), and calendar-year of AIDS diagnosis (1980-1989, 1990-1995, and 1996-2005). We used the most recent value for CD4 lymphocyte count at AIDS during six months before to three months after AIDS diagnosis. Calendar-year period reflected progressive improvement in anti-
retroviral therapies, i.e., no or mono therapy, mono or dual therapy, and highly active antiretroviral therapy (HAART). Rates were only presented for categories with 10 or more cases to avoid presenting unstable rates, consistent with the practice of the International Agency for Research on Cancer. Statistical tests were two-tailed, and $p$-values $<0.05$ were considered statistically significant.

Because we previously observed trimodal peaks in BL from SEER $^8$, we plotted age-specific incidence rates for BL by six age groups on a log (y) and linear (x) scale, such that a slope of 10 degrees equaled a 1% per year change in rates $^{17}$, to assess whether trimodal age-specific patterns were present in immunosuppressed persons. We also plotted log BL incidence by four CD4 lymphocyte groups to explore the risk patterns with immunosuppression, given that BL occurs over a wide range of CD4 lymphocyte counts. Log incidence rates for other NHLs were plotted by age and CD4 lymphocytes for comparative purposes. Analyses were performed using the SAS, version 9.1 (SAS Institute Inc, Cary, North Carolina, USA).

**Results**

We analyzed 1,103 cases of BL, including 797 that were prevalent and 306 that were incident, among 567,865 PWA followed for an average of 2.4 years. By comparison, we identified 15,730 other NHLs, including 7,580 prevalent and 8,150 incident cases, during the same follow-up period. The mean ages for prevalent and incident BL were similar (38.3 versus 38.5 years, $p=0.48$). In contrast, the mean age for prevalent other NHLs was on average three years
younger than the mean age for incident other NHLs (38.1 years versus 41.1 years, \( p < 0.001 \)). Table 1 shows the demographic characteristics of PWA studied, the numbers of incident BL, the crude incidence rates, and the crude and multivariate-adjusted incidence rate ratios (aIRR). As expected, most BL (89.2\%) were aged 20-51 years, and only 3.3\% were aged <20 years and 7.5\% were aged 52 years or older.

Overall BL incidence was 22.0 per 100,000 persons (Table 1). The crude and adjusted incidence rate ratios were different for some variables, suggesting confounding was present, so both the crude and adjusted incidence rate ratios are reported (Table 1). The crude male to female IRR was reduced from 2 to 1.6 (95\% CI 1.1-2.3) in the adjusted model, and the aIRR was lower in non-Hispanic Black than non-Hispanic White PWA (0.4, 95\% CI 0.3-0.5). Compared to MSM, the crude BL incidence rates were lower in PWA whose HIV transmission risk category was IDU or heterosexual, but the differences became non-significant in multivariate-adjusted analysis. Compared to PWA aged 32-39 years, the crude IRR for BL was non-significantly elevated among PWA aged 0-19 years (1.6, 95\% CI 0.8-3.0), but it became significant in multivariate analysis (2.3, 95\% CI 1.2-4.4). The crude and adjusted IRR for BL among PWA aged 20-31 years were significantly decreased (both 0.6, 95\% CI 0.4-0.8), but the crude and adjusted IRR for BL among PWA aged 40-51 years, 52-59 years and those aged 60 years or older were not significantly different. The crude and adjusted IRR for BL were notably lower among PWA having <50 CD4 lymphocyte cells/\( \mu \)L than those with
>250 cells/µL at AIDS (aIRR 0.3, 95% CI 0.2-0.6). The BL rate among PWA declined over time from 1980-1989 to 1996-2005.

The age-specific incidence rates for BL suggested three peaks during the pediatric, adult, and geriatric years, although the adult confidence limits overlapped (Figure 1, Panel A). In contrast, age-specific incidence rates for other NHLs increased from childhood to adulthood and stabilized thereafter (Figure 1A, Panel A). The risk for other NHLs was six times that of BL among those aged 0-19 years, 24-40-fold among those aged 20-59 years, and 15-fold among those ≥60 years (Figure 1, Panel A).

The incidence of BL declined steeply with CD4 lymphocyte counts <50 cells/mL at AIDS (Figure 1, Panel B). In contrast, the incidence for other NHLs increased consistently with decreasing CD4 lymphocyte counts (Figure 1, Panel B). The risk for other NHLs was nine times that of BL among those with >250 cells/µL, 17-fold among those with 50-259, and 66-fold among PWA with <50 cells/µL.

**Discussion**

The major findings were bimodal and perhaps trimodal age-specific BL incidence peaks, significant decline in BL risk at low CD4 lymphocyte counts at AIDS, and lack of association between risk for BL and HIV transmission risk categories, which are a surrogate for sexual and blood-borne infections that are highly prevalent in the US HIV/AIDS population. Our finding of bimodal or trimodal BL incidence peaks in PWA replicates our results in the U.S. general
population, and suggests that bi/trimodality of BL may occur independently of severe immunosuppression. The notion that BL may be multimodal is controversial. Several malignancies, including lymphoblastic leukemia, Hodgkin lymphoma, kidney and renal pelvis cancer, brain cancer are bimodal.

However, BL is considered isomorphic and mostly a pediatric lymphoma, with occasional cases diagnosed at other ages. Multimodality in cancer suggests a mixture of two or more types of cancer that resemble and are coded as one. For BL, the types may include the well accepted pediatric BL as one type and a mixture of the adult and/or geriatric BL as the other type(s). If so, the pediatric and adult/geriatric types might have different risk factors, different pathogenesis pathways, and different molecular characteristics. Whether the subtle variation in morphologic, cytogenetic, and molecular patterns in BL is related to the age-specific incidence patterns we observed is unknown, but worth investigating.

Our finding that risk for BL declined steeply at very low CD4 lymphocyte counts is surprising, given that risk for BL, as for others lymphomas, is attributed to deleterious effects of HIV or oncogenic infections, such as EBV, and/or growth factor expression in altered immunostates, which are normally most expressed at low CD4 lymphocyte counts. Although, some pioneer studies have noted a link between CD4 lymphocyte counts and BL, our study however, represents the largest study of AIDS related BL and was able to look at age-specific and CD4 count-specific BL risk, and therefore represents a major extension of the findings from these previous studies. Our results and historical data indicate that the risk for BL peaks at CD4 lymphocyte counts well above
the laboratory cutoff for AIDS onset (200 cells/µL), provocatively suggesting that its expression may require functional CD4 lymphocytes. The higher risk for BL during 1980-1989 than later may reflect a larger portion of recent HIV infections with relatively higher CD4 lymphocyte counts in that period than later, a shift in the demographic profile of the U.S. AIDS epidemic from predominantly non-Hispanic White men, whose risk for BL is higher, to predominantly non-Hispanic Black men, Hispanics and women, whose risk for BL is lower, or to access to HAART after 1996. In the HACM study, the proportion of Blacks, who have a lower risk for BL compared to Whites, increased from 30% in 1980-1989 to 39% in 1990-1995 to 50% in 1996-2005. Conversely, the proportion of Whites, whose risk for BL is higher than Blacks, decreased from 54% in 1980-1989, to 41% in 1990-1995 and to 29% in 1996-2005. Possibly, the paradoxical relationship between risk for BL and CD4 lymphocyte counts may be a clue to a physiological role of functional CD4 lymphocytes in BL lymphomagenesis.

Burkitt lymphoma is a germinal center (GC) tumor. The seminal event in BL, the c-myc:Immunoglobulin (Ig) translocation, is thought to occur as a result of an error in activation-induced cytidine deaminase (AID)-mediated Ig class switch recombination in GCs, an event that is driven in B-cells that are activated by exposure to antigen and CD4 lymphocyte help in the GC. High expression of AID in peripheral blood mononuclear cells has been shown to precede the development of BL by up to 8 years in HIV-infected patients, consistent with AID-mediated c-myc/Ig abnormalities preceding the development of BL. However, frequent and persistent detection of single or multiple clones of
c-myc/Ig translocation bearing B-cells, although elevated with HIV infection \(^{37}\), did not predict NHL or BL, suggesting that presence of c-myc/Ig-clonotypic cells, per se, is insufficient to cause rapidly growing lymphomas. The relationship between AIDS expression and/or c-myc/Ig-translocation-positive B-cell clones and CD4 lymphocyte counts is unknown. CD4 lymphocytes may be required to rescue c-myc/Ig translocation-positive clonotypic B cells from programmed cell death. Chronic HIV infection disrupts the GC reaction \(^{38}\), leads to depletion of GC- and peripheral blood-CD4 lymphocytes \(^{39}\), and without a cognate CD4 lymphocyte-cell help, B-cells are shunted into programmed cell death. In the absence of cognate help from CD4 lymphocytes, GC B-cell activation would decrease and, therefore, the rate of generating c-myc/Ig translocation positive B-cells would decrease, which would account for the deficit of BL at low CD4 lymphocyte counts. The low CD4 lymphocyte counts, however, could be a marker for other exposures, which could also reduce the rate of generation of translocations and lower risk for BL, such as substantial non-specific destruction of lymph nodes and atrophic GC reaction in advanced HIV disease \(^{40}\). Non-specific disruption of B-cell production, however, is unlikely to be the explanation, given the continuing risk of other B-cell NHLs at low CD4 lymphocyte counts.

Our study is the largest to assess age-specific incidence of BL among persons with AIDS. Even so, the small number of cases in some categories, such as age groups 52-59 years and >60 years, prevented us from obtaining stable estimates of fluctuating risk with age to definitively show trimodality. Lack of centralized tumor pathology review is a limitation, however, misclassification of
BL diagnosis by age or CD4 lymphocyte count groups is likely to be random and unlikely to explain the results. We lacked CD4 lymphocyte counts after AIDS, thus, patterns of CD4 lymphocyte counts at BL, which may be more relevant to etiology could not be assessed.

To summarize, BL among PWA in the U.S. was characterized by at least two and perhaps three age-specific incidence peaks, suggestive of bimodality and perhaps trimodality, and BL incidence declined at low CD4 lymphocyte counts, suggesting functional CD4 lymphocytes may be required for BL to develop.
ACKNOWLEDGEMENT

We thank the staff at the HIV/AIDS and cancer registries at the following locations: Colorado; Connecticut; Florida; Illinois; Georgia; Massachusetts; Michigan; New Jersey; New York City, New York; Los Angeles, San Diego and San Francisco, California; Seattle, Washington; Texas; and Washington, D.C. We thank Mr. Tim McNeel of Information Management Services, Inc, (Silver Spring, Maryland) for creating the dataset for analysis. We thank Dr. Otoniel Martinez-Maza (University of California, Los Angeles, California) for comments on the manuscript. This work was supported by the Intramural Research Program of the National Cancer Institute (contracts N02-CP-31003 and N01-CO-12400), National Institutes of Health, Department of Health and Human Services.

AUTHORS CONTRIBUTION

M Guech-Ongey analyzed and interpreted data, and drafted the manuscript. E Simard analyzed and interpreted data. W F Anderson analyzed and interpreted data. K Bhatia interpreted data. E. A. Engels is the Principal Investigator of the National Cancer Institute’s HIV/AIDS Cancer Match Study; he contributed to analysis and interpreted data. SS Devesa interpreted data and critically edited the paper. S M Mbulaiteye conceived the idea, guided data analysis, interpreted data and edited the paper. All authors had access to data, commented on and contributed to the final draft of the manuscript.

CONFLICT OF INTEREST

None declared
References


Table 1: Crude incidence and incidence rate ratios for Burkitt lymphoma among persons with AIDS in the United States, 1980-2005

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of subjects (%)</th>
<th>Number of incident BL cases</th>
<th>Crude incidence rate, per 100,000 person-years</th>
<th>Crude incidence rate ratios (95% CI)</th>
<th>Adjusted incidence rate ratios (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>567865 (100)</td>
<td>306</td>
<td>22.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>456635 (80.4)</td>
<td>273</td>
<td>24.4</td>
<td>2.0 (1.4 – 2.9)</td>
<td>1.6 (1.1 – 2.3)</td>
</tr>
<tr>
<td>Female</td>
<td>111230 (19.6)</td>
<td>33</td>
<td>12.2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Race/ethnicity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic white</td>
<td>218917 (38.5)</td>
<td>168</td>
<td>30.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic black</td>
<td>235578 (41.5)</td>
<td>54</td>
<td>9.6</td>
<td>0.3 (0.2 – 0.4)</td>
<td>0.4 (0.3 – 0.5)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>113370 (20.0)</td>
<td>84</td>
<td>30.9</td>
<td>1.0 (0.8 – 1.3)</td>
<td>1.2 (0.9 – 1.5)</td>
</tr>
<tr>
<td><strong>Mode of HIV transmission</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>281365 (49.6)</td>
<td>190</td>
<td>26.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDU</td>
<td>137533 (24.2)</td>
<td>49</td>
<td>15.5</td>
<td>0.6 (0.4 – 0.8)</td>
<td>0.7 (0.5 – 1.0)</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>70283 (12.4)</td>
<td>23</td>
<td>12.7</td>
<td>0.5 (0.3 – 0.7)</td>
<td>0.7 (0.5 – 1.1)</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>78630 (13.9)</td>
<td>44</td>
<td>25.1</td>
<td>1.0 (0.7 – 1.3)</td>
<td>1.2 (0.8 – 1.8)</td>
</tr>
<tr>
<td><strong>Age at AIDS-onset, years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 – 19</td>
<td>9339 (1.6)</td>
<td>10</td>
<td>39.5</td>
<td>1.6 (0.8 – 3.0)</td>
<td>2.3 (1.2 – 4.4)</td>
</tr>
<tr>
<td>20 – 31</td>
<td>129139 (22.7)</td>
<td>49</td>
<td>14.2</td>
<td>0.6 (0.4 – 0.8)</td>
<td>0.6 (0.4 – 0.8)</td>
</tr>
<tr>
<td>32 – 39</td>
<td>200765 (35.4)</td>
<td>125</td>
<td>24.7</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>40 – 51</td>
<td>175019 (30.8)</td>
<td>99</td>
<td>24.2</td>
<td>1.0 (0.8 – 1.3)</td>
<td>1.0 (0.8 – 1.3)</td>
</tr>
<tr>
<td>52 – 59</td>
<td>35450 (6.2)</td>
<td>13</td>
<td>17.9</td>
<td>0.7 (0.4 – 1.3)</td>
<td>0.8 (0.4 – 1.4)</td>
</tr>
<tr>
<td>≥ 60</td>
<td>18153 (3.2)</td>
<td>10</td>
<td>31.7</td>
<td>1.3 (0.7 – 2.4)</td>
<td>1.4 (0.7 – 2.7)</td>
</tr>
<tr>
<td><strong>CD4 lymphocyte count /uL</strong>†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 – 49</td>
<td>108512 (31.4)</td>
<td>23</td>
<td>9.6</td>
<td>0.3 (0.2 – 0.5)</td>
<td>0.3 (0.2 – 0.6)</td>
</tr>
<tr>
<td>50 – 149</td>
<td>111304 (32.2)</td>
<td>90</td>
<td>29.8</td>
<td>1.0 (0.7 – 1.5)</td>
<td>1.0 (0.7 – 1.5)</td>
</tr>
<tr>
<td>150 – 249</td>
<td>91315 (24.4)</td>
<td>67</td>
<td>23.9</td>
<td>0.8 (0.5 – 1.2)</td>
<td>0.8 (0.5 – 1.2)</td>
</tr>
<tr>
<td>250 +</td>
<td>34183 (9.8)</td>
<td>33</td>
<td>30.7</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Missing §</td>
<td>120902 (25.9)</td>
<td>36</td>
<td>13.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Calendar year of AIDS onset</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980 – 1989</td>
<td>101649 (17.9)</td>
<td>57</td>
<td>29.4</td>
<td>1.3 (1.0 – 1.8)</td>
<td>1.6 (1.1 – 2.4)</td>
</tr>
<tr>
<td>1990 – 1995</td>
<td>247922 (43.7)</td>
<td>146</td>
<td>22.5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>1996 - 2005</td>
<td>218294 (38.4)</td>
<td>103</td>
<td>18.8</td>
<td>0.8 (0.6 – 1.1)</td>
<td>0.9 (0.7 – 1.1)</td>
</tr>
</tbody>
</table>

* MSM= men who have sex with men; IDU= intravenous drug users; † Incidence rate ratio for BL for each factor is adjusted for all other factors in the table; records with missing CD4 data were coded as missing and included in the model; ‡ CD4 lymphocyte count analyses based on data from 1990 – 2005; § percentage of the CD4 lymphocyte counts for missing are of the total; for known categories, the percentages are based on those with known CD4 lymphocyte counts.
Figure legend

**Figure 1:** Log incidence rates for Burkitt lymphoma (open circles) and for other non-Hodgkin lymphomas (other NHLs), excluding Burkitt lymphoma, (open squares) by age group (0-19, 20-31, 32-39, 40-51, 52-59, and >60 years) (Panel A) and by four CD4 lymphocyte count groups (0-49, 50-149, 150-249, and >250 cells/µL) (Panel B). Dotted lines show the upper and lower 95% confidence intervals.
Figure 1:

A: 
Rate per 100,000 person-years
Age at diagnosis

B: 
Rate per 100,000 person-years
CD4 Lymphocyte count
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?


Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.